Business Context and Reporting Period
This Form 8-K was filed by Daxor Corporation (DXR) on November 27, 2023, with the earliest event reported on that date. The filing addresses Item 8.01 (Other Events) to provide specific details regarding the allocation of proceeds from a public offering conducted on May 22, 2023. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, primarily marketing the FDA-cleared BVA-100 Blood Volume Analyzer.
Key Financial Metrics
The filing does not report current period revenue, profit, cash flow, margins, or debt levels. The only financial data provided relates to a prior capital raise:
- Offering Date: May 22, 2023
- Shares Issued: 410,260
- Price Per Share: $9.75
- Net Proceeds Raised: $3,555,532
- Specific Allocation: $550,000 reserved for proprietary hematocrit capability development.
Material Changes and Use of Proceeds
The material change disclosed is the specific designation of funds from the May 2023 offering. The Company announced that $550,000 of the net proceeds has been reserved to support the development of a proprietary hematocrit capability. This development is intended to be compatible with the Company's next-generation technologies.
Outlook, Management Commentary, and Risks
Development Timeline: The Company anticipates the hematocrit development work will proceed over a 12-month period. This effort will be conducted in conjunction with other technology development efforts supported by the Department of Defense.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding product development, commercialization, market acceptance, and regulatory actions. Risks cited include post-market clinical data collection, competitive offerings, intellectual property protection, and FDA regulatory actions. The Company states it does not assume an obligation to update these statements.
Investor Verification Checklist
- Verify the total cash balance and liquidity position in the most recent 10-Q or 10-K to assess runway for the 12-month development period.
- Confirm the status of the Department of Defense support mentioned for next-generation technologies.
- Review the original May 22, 2023 offering documents (Form 497) to compare the initial stated use of proceeds against this specific allocation.
- Monitor future filings for updates on the proprietary hematocrit capability development milestones.